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The transmembrane protein with epidermal growth factor
and two follistatinmotifs 2 (TMEFF2) is expressed in prostate
and brain and shed from the cell surface in ametalloproteinase-
dependent fashion. Neither the sheddase(s) responsible for
TMEFF2 shedding nor the physiological significance or activity
of the soluble TMEFF2 ectodomain (TMEFF2-ECD) has been
identified. In the present study we present new evidence that a
disintegrin andmetalloproteinase-17 (ADAM17) is responsi-
ble for phorbol 12-myristate 13-acetate-induced release of
TMEFF2-ECD using small interfering RNA to ablate ADAM17
expression or by inhibiting enzymatic activity. A single well
shedding assay monitoring the release of alkaline phosphatase-
tagged TMEFF2-ECD into medium and the generation of 22-
and 14-kDa C-terminal fragments in lysates were dependent on
ADAM17 activity. A -secretase inhibitor prevented the forma-
tionofa10-kDa fragment incell lysates, thusestablishingTMEFF2
as a novel substrate for regulated intramembrane proteolysis. We
assigned proliferation-inducing activity to TMEFF2. Inhibition of
TMEFF2 shedding using syntheticmetalloproteinase inhibitors or
small interferingRNA targetingTMEFF2 expression yielded a sta-
tistically significant reduction of cell proliferation in the lymph
node-derived prostate cancer cells (LNCaPs) and a human embry-
onic kidney (HEK293) cell line overexpressing TMEFF2. The
TMEFF2-ECD was able to induce ERK1/2 phosphorylation in an
epidermalgrowthfactorreceptor (orErbB1)-dependentmanner in
HEK293 cells. Our data suggest that TMEFF2 contributes to cell
proliferation in an ADAM17-dependent autocrine fashion in cells
expressing this protein.
The transmembrane protein with epidermal growth factor
and two follistatinmotifs 2 (TMEFF2)2 gene encodes amodular
protein consisting of two follistatin modules, an epidermal
growth factor (EGF)-like repeat, and a transmembrane domain
connected to a short cytoplasmic tail with a potential G-protein
activation motif. TMEFF2 is highly up-regulated in 74% of pri-
mary prostate cancer (PCa) and 42% of metastatic lesions from
lymph nodes and bone irrespective of hormonal disease status
(1). TMEFF2 expression correlates with onset of cellular prolif-
eration after castration in the CWR22 PCa mouse model (2) as
well as in the TEN12 xenograft model (3), suggesting that it is
not a tumor suppressor (1). However, in a different LNCaP
human PCa progression model opposing results were obtained
whereTMEFF2 expressionwas highest in low grade disease and
down-regulated in aggressive metastatic C4-2 xenografts (4).
TMEFF2 expression is absent in androgen-independent PCa
cell lines PC3 and DU145 (5). When TMEFF2 expression was
re-established in PC3 and DU145 cell lines by stably transfect-
ing these cell lines with TMEFF2 cDNA a 50% decrease in cell
proliferation was observed (5), but this finding could not be
corroborated by Afar et al. (1).
The biological function of TMEFF2 in PCa is unknown, but it
has been implicated in cell signaling (6), neuronal cell survival
(7), tumor suppression (5, 8, 9), and Alzheimer disease (10).
Uchida et al. (6) showed that the TMEFF2-ECD induced tyro-
sine phosphorylation of ErbB4, an epidermal growth factor
receptor/ErbB family member in MKN28 gastric cancer cells.
However, it is unlikely that the TMEFF2-ECD is able to induce
ErbB4 phosphorylation in PCa as this receptor tyrosine kinase
is not expressed in PCa cell lines (11, 12).
TMEFF2 ectodomain shedding is induced by proinflamma-
tory cytokines such as interleukin-1 and tumor necrosis fac-
tor- (TNF-) in A172 glioma cells (13) and is mediated by
unknown metalloproteinase(s). This finding implied to us that
TMEFF2 release may be the result of proteolytic processing by
membrane-anchored metalloproteinases of the ADAM (a dis-
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integrin and metalloproteinase) family as these enzymes are
major regulators of protein ectodomain shedding (for a review,
see Ref. 14). An increasing number of transmembrane proteins
are released from the cell surface by ectodomain shedding,
which ismainly but not exclusivelymediated bymembers of the
ADAM family of metalloproteinases (14). The substrate spec-
trum of the ADAM family reaches from syndecans, cadherins,
the hyaluronan receptor CD44, the tumor necrosis factor
receptor, fractalkines, mucins, FAS ligand, the receptor activa-
tor of NFB ligand (RANKL), Notch, the amyloid  precursor
protein, ephrins to EGF-like growth factors, their receptors
ErbB2 and ErbB4 to receptor tyrosine phosphatases, vascular
adhesion molecule, and other proteins (15–31). Therefore the
biological spectrum of ADAM function is currently rapidly
expanding as these enzymes play important roles in regulating
signaling, cell adhesion or repulsion, migration, proliferation,
and cell death. ADAMs play fundamental roles in regulating
development, morphogenesis, and diseases such as arthritis
and cancer. The proteolytic activity of ADAMs is regulated in
part by the tissue inhibitors ofmetalloproteinases (TIMPs)with
TIMP3 displaying the broadest range of inhibitory capability
toward various ADAM family members, such as ADAM10,
ADAM17, or the soluble ADAM12 variant (32–34), whereas
others are not regulated by TIMPs. These initial in vitro find-
ings are now increasingly corroborated by interesting pheno-
types from the TIMP3-null mice demonstrating a broad range
of activities linking TIMP3 loss with increased ADAM or
ADAM with thrombospondin motifs (ADAMTS) activity in
affected tissues, such as heart, joints, and the immune system
among others (35–39).
In cancer, a major function of ADAMs is to regulate the bio-
availability of the ErbB ligands, thereby triggering signal trans-
mission through the ErbB receptor tyrosine kinase network (14,
26, 40–42). Some ligands are able to convey signals in juxta-
crine mode when still attached to the cell membrane (43), but
there is now ample evidence that ectodomain release from the
cell surface is a prerequisite for most ligands to signal via their
appropriate ErbB receptor tyrosine kinases (44–46). The cor-
responding membrane-associated ligands therefore mostly
represent inactive precursors. Aberrant ErbB signaling has
been identified as a contributor to malignant transformation
where these proteins contribute to aggressive cancer pheno-
types (47). Therapeutic approaches now target breast cancer
with anti-ErbB2 antibodies in overexpressing tumors, and
small synthetic ErbB1 receptor tyrosine kinase inhibitors are
used to block aggressive growth of lung cancer (40, 48, 49).
We hypothesized that the release of the TMEFF2-ECD
would result in downstream signaling events that may drive
proliferation in cells expressing this protein and possibly acti-
vate ErbB signaling due to the amount of homology between
TMEFF2 and the EGF-like/neuregulin family of growth factors.
Here we present evidence that TMEFF2 is a new ADAM17 and
-secretase substrate and demonstrate for the first time that the
TMEFF2-ECD has growth promoting activity in an HEK293
TMEFF2 overexpression model system by activating ERK1/2
phosphorylation in an ErbB1-dependent manner. Our work
implies that ADAM17 and TMEFF2 targeting would benefit
PCa sufferers.
EXPERIMENTAL PROCEDURES
Reagents—Synthetic metalloproteinase inhibitors, the
-secretase inhibitor DAPTwere purchased from Calbiochem.
Anti-TMEFF2 antibody was from R&D Systems, and anti-V5
epitope antibody was from Invitrogen. Anti-mouse or anti-rab-
bit secondary peroxidase-conjugated antibodies were from
Jackson ImmunoResearch Laboratories. The protease inhibitor
cocktail and the ErbB1 inhibitor tyrphostin (AG1478) were
from Sigma. The generation of TMEFF2 expression constructs,
overexpression cell lines, and shedding conditions are detailed
in the supplemental information. Expression constructs are
schematically shown in Fig. 1.
Analysis of TMEFF2 Shedding by Western Blotting—Cells
were seeded at the indicated cell densities in 6-well plates (see
figure legends) and grownovernight. Serum-containing growth
medium was removed, and monolayers were washed with
phosphate-buffered saline prior to treatmentwith various com-
pounds in serum-free medium for variable periods of time as
indicated in the respective figure legends. Medium was
removed, cells were washed twice with phosphate-buffered
saline, and lysed in RIPA buffer (20 mM sodium phosphate, pH
7.4, 150 mM NaCl, 1% Triton X-100 supplemented with pro-
teinase inhibitor mixture (Sigma) and 250 g/ml sodium vana-
date). Cell debris were removed by centrifugation, and protein
content was determined using the DC protein assay (Bio-Rad)
prior to equal loading of lysates for 12.5 or 10% SDS-PAGE and
Western blotting. Proteins were detected using anti-TMEFF2
(1:1,000), or anti-V5 (1:5,000) primary antibodies with appro-
FIGURE 1. Schematic representation of mammalian TMEFF2 expression
constructs and maltose-binding fusion proteins of the complete or the
EGF-like domain of TMEFF2. FS, follistatin module; EGF, EGF-like repeat; T,
transmembrane domain, cyto, cytoplasmic tail; HA, HA epitope tag; V5, V5
epitope tag; Flag, FLAG epitope tag; Calm, calmodulin binding domain; His,
His6 tag; black box, juxtamembrane stalk sequence motif (residues 303–320).
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priate secondary antibodies conjugated to horseradish peroxi-
dase (1:5,000 or 1:10,000) allowing visualization using
enhanced chemiluminescence (Pierce). Equal loading was ver-
ified using a mouse monoclonal GAPDH antibody (at 1:20,000;
Advanced Immunochemical).
Quantifiable Shedding of Alkaline Phosphatase (AP)-tagged
TMEFF2 (AP-TMEFF2)—To be able to sensitively follow
TMEFF2 shedding we used the AP-TMEFF2-expressing cell
line to detect release of AP activity into the medium during
PMA-induced shedding. The assay was performed as described
by Sahin et al. (26, 50) for AP-tagged ErbB ligands.
Knockdown of ADAMs by siRNA—The following siRNA oligo-
nucleotides were used to ablate ADAM-9, -10, and -17 gene
expression: control, UAGCGACUAAACACAUCAAUU;
ADAM-17, GAGGAAGCAUCUAAAGUUUUU; ADAM-10,
GGACAAACUUAACAACAAUUU; and ADAM-9, AAUG-
UACAAGAGAUACCUGUA.
The siRNA transfectionswere performed according toDhar-
macon’s protocol. Briefly cells were seeded at 6 105 cells/well
in polylysine-coated 6-well dishes and grown overnight. 4 l of
Dharmafect transfection reagent was diluted in 200 l of
serum-free medium prior to addition of prediluted 100 nM
siRNA and incubation for 20 min. Spent growth medium was
removed and replaced with 1.6 ml of fresh medium and 400 l
of the siRNA transfection mixture. Transfections were
repeated 48 h later prior to induction of TMEFF2 shedding
following a total of 4 days of siRNA treatment. Results shown
are representative for two independent experiments performed
in duplicate.
Knockdown of TMEFF2 in LNCaPs and TMEFF2-overex-
pressing HEK293 Cells Using siRNA and Analysis of Cell
Proliferation—TMEFF2-overexpressing HEK293 cells and
LNCaP cells were seeded at 1  104 cells/well using a 96-well
plate. The next day siRNA transfections were carried out
using Dharmacon SmartPool siRNA (M-010654-00-0020).
The SmartPool siRNA targets the coding sequences for the
extracellular domain of TMEFF2. A dose of 100 nM was used.
For each cell line two independent experiments with 15
repeats for each treatment were analyzed using the MTT
assay 4 days later. Alternatively TNF--induced shedding
was analyzed in siRNA-treated LNCaP and HEK293 cells
expressing TMEFF2 by Western blot analysis of conditioned
medium.
Cell Proliferation Assays—Cells overexpressing full-length
TMEFF2 or TMEFF2-ECD were seeded at 2,500 cells/well in a
96-well plate and grown overnight. The next day the medium
was removed and replaced with 1% serum-containing medium
supplemented with solvent or TNF- protease inhibitor
(TAPI-1) to prevent shedding in case of full-length TMEFF2.
Following a 4-day growth period, 30 l of MTT solution (5
mg/ml; Sigma) was added to each well prior to addition of 100
l of lysis solution 4 h later. Following a 1-h incubation period,
plates were read at 570 nm. Alternatively experiments were
performed using non-transfected HEK293 cells and purified
recombinant TMEFF2-ECD.
Analysis of ErbB1-dependent ERK1/2 Phosphorylation by
TMEFF2-ECD and EGF-TMEFF2—Cells grown in 24-well
plates were serum-starved overnight prior to stimulation with
the indicated amounts of TMEFF2-ECD in the appropriate
growth medium in the presence or absence of AG1478. Cells
were harvested into SDS sample buffer (1% SDS, 1% dithiothre-
itol, 62.5 mM Tris/HCl, pH 6.8, 10% glycerol, 100 mM sodium
fluoride, 10 mM sodium pyrophosphate, 1 mM sodium
orthovanadate, 0.01% bromphenol blue), heated to 100 °C for 5
min, and analyzed by SDS-PAGE and Western blotting as
described above but using 1% Blocking Agent (Roche
Applied Science) in 50 mM Tris/HCl, pH 7.5, 150 mM NaCl
containing 0.05% Tween 20. The membranes were probed
overnight with mouse antibodies against phosphorylated
ERK1/2 (Thr202/Tyr204; 1:5,000; Cell Signaling Technolo-
gies) in Blocking Agent (Roche Applied Science). Washed
membranes were incubated for 1 h with secondary anti-
mouse IgG-peroxidase conjugate in Blocking Agent and
developed as described above. To test for uniform gel load-
ing and transfer to the membrane, the blots were then rep-
robed with an anti-GAPDH antibody diluted 1:20,000 in
Blocking Agent for 1 h and detected as above.
Statistical Analysis—Statistical analysis was performed using
ANOVA with post-test Tukey analysis for experiments with
more than one variable. Student’s t test was performed for
experiments with one variable only. Proliferation experiments
were repeated twice.
RESULTS
Shedding of TMEFF2 Is Induced by TNF- in LNCaPs and
TMEFF2-overexpressing HEK293 Cells
To confirm that the introduction of an IgG secretion
sequence, N-terminal HA tag, and C-terminal V5/His tags
had no consequences on TNF--induced TMEFF2 shedding
we compared TMEFF2-ECD release in LNCaPs, which nat-
urally express this protein, with shedding of tagged TMEFF2
from stably transfected HEK293 cells. Cells were grown to
90% confluency prior to TNF- stimulation of TMEFF2
shedding in serum-free conditions for 12 h. These condi-
tions allowed accumulation of sufficient soluble TMEFF2-
ECD into the medium. Concentrated medium was analyzed
by Western blotting using a commercial TMEFF2 antibody
that recognizes the ectodomain of the protein. As shown in
Fig. 2A TNF- treatment of both LNCaPs and HEK293 cells
expressing tagged TMEFF2 resulted in a dramatic increase of
soluble TMEFF2-ECD in conditioned medium (Fig. 2A,
lanes 2 and 4) when compared with non-stimulated controls
(Fig. 2A, lanes 1 and 3). This is in good agreement with data
published previously (3), and we will refer to HA- and
V5/His-tagged TMEFF2 as TMEFF2 from now on for sim-
plicity. Additional experiments were performed to analyze
shedding in these two cell lines using the phorbol ester PMA.
As shown in Fig. 2B (lane 6) PMA-induced TMEFF2 shed-
ding in the TMEFF2 overexpression HEK293 cell model.
LNCaP cells showed similar results but started to undergo apo-
ptotic changes in the presence of PMA (not shown), and thus
further PMA shedding experiments were performed with
TMEFF2-overexpressing HEK293, Chinese hamster ovary, or
PC3 cell model systems.
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Phorbol Ester (PMA)-induced TMEFF2-ECD Release Is
Dependent on Metalloproteinase Activity but Not on
-Secretase Activity
To test the hypothesis that TMEFF2 is shed from the cell
surface by members of the metalloproteinase family we ana-
lyzed constitutive and PMA-induced processing in the pres-
ence and absence of the synthetic metalloproteinase inhibitor
GM6001 or the -secretase inhibitor DAPT in HEK293 cells
expressing TMEFF2 or AP-TMEFF2 (see Fig. 1 for details).
Cells were stimulated for 1 h with PMA in serum-free condi-
tions followed by removal of PMA to prevent toxic effects and a
further 7-h incubation period in the
presence or absence of the inhibi-
tors to allow accumulation of
TMEFF2-ECD in the medium. As
shown in Fig. 2B (Medium panel)
PMA strongly induced release of
TMEFF2-ECD (Fig. 2B, lane 6),
which was inhibited in the presence
of GM6001 (Fig. 2B, lane 5). In con-
trast, the -secretase inhibitor
DAPT had no effect on the release
of TMEFF2-ECD into the medium
(Fig. 2B,Medium panel, lane 4). To
be able to quantitate TMEFF2-ECD
release we compared AP-TMEFF2
shedding with TMEFF2 release
from the cell surface following PMA
stimulation. As shown in Fig. 2C
AP-TMEFF2 was processed in a
manner similar to that of TMEFF2
but released a 140-kDa fragment
into the medium corresponding to
AP-TMEFF2-ECD following a 7-h
accumulation period. We then used
the AP-TMEFF2-expressing cells to
quantify AP-TMEFF2-ECD release
in single well shedding assays
described by Sahin et al. (50) to con-
firm the effects of inhibitor treat-
ment as described above using only
a 1-h PMA stimulation. These
experimental conditions were sen-
sitive enough to allow us to monitor
constitutive as well as PMA-in-
duced AP-TMEFF2-ECD release,
which was not possible by Western
blotting. As shown in Fig. 2D PMA-
induced or constitutive release of
AP-TMEFF2-ECD into themedium
was inhibited byGM6001 treatment
(56%of constitutive release). In con-
trast, the -secretase inhibitor
DAPT was unable to block
TMEFF2-ECD release as expected.
Additional experiments were per-
formed using a combination of
GM6001 and DAPT, which also
inhibited TMEFF2-ECD cleavage from the cell surface and
reached the same value as GM6001 treatment alone (Fig. 2D).
Generation of C-terminal TMEFF2 Fragments Is Affected by
Both Metalloproteinase and -Secretase Inhibitors
To determine whether the metalloproteinase and -secre-
tase inhibitors affected the formation of C-terminal TMEFF2
fragments we analyzed cell lysates by Western blotting. Analy-
sis of lysates from non-stimulated and PMA-induced cells fol-
lowing a 7-h accumulation period showed the presence of 22-,
14-, and 10-kDa fragments in solvent control lanes (Fig. 2B, lane
FIGURE 2. A, TMEFF2 shedding is induced by TNF- in LNCaPs or HA-TMEFF2-V5/His-overexpressing HEK293
cells: detection of soluble fragments in medium. Lanes 1 and 3, controls; lanes 2 and 4, medium following TNF-
treatment for 12 h. Specific bands were identified at 75 and 60 kDa that correspond to the expected molecular
mass of the TMEFF2-ECD. B, PMA-induced TMEFF2 shedding is dependent on metalloproteinase activity: anal-
ysis of medium and lysates from double tagged TMEFF2-expressing HEK293 cells following 7-h accumulation
of fragments. Lanes 1–3, unstimulated cells treated with 5 M DAPT (lane 1), 50 M GM6001 (lane 2), or Me2SO
vehicle (lane 3). Lanes 4 – 6, PMA-treated cells treated with 5 M DAPT (lane 4), 50 M GM6001 (lane 5), or Me2SO
vehicle (lane 6). Medium was concentrated 10-fold and analyzed using anti-TMEFF2 antibody (top panel).
Lysates were analyzed using the V5 epitope antibody to stain for C-terminal fragments (middle panel). A GAPDH
loading control is shown to demonstrate equal loading of lysates (bottom panel). C, AP-TMEFF2 shedding is
induced by PMA: analysis of medium following 7-h accumulation of fragments. Lanes 1 and 2, AP-TMEFF2: lane
1, vehicle control; lane 2, PMA-stimulated. Lane 3 and 4, TMEFF2: lane 3, vehicle control; lane 4, PMA-stimulated.
The Western blot is stained with anti-TMEFF2 antibody. D, AP-TMEFF2-ECD release after 1-h induction with
PMA is blocked by GM6001. Single well shedding assays were performed using eight replicas for each treat-
ment and a 1-h incubation period for PMA stimulation (50). Alkaline phosphatase activity was monitored by
hydrolysis of p-nitrophenyl phosphate. Background AP activity from non-transfected cells was subtracted.
Data are represented as mean  S.E. of six replicas, and inhibitor treatment is indicated. E, C-terminal TMEFF2
processing depends on both metalloproteinase and -secretase activities: analysis of lysates from transiently
transfected PC3 and stably transfected Chinese hamster ovary (CHO) cells. The inhibitor treatment and staining
with V5 epitope antibody was performed as described in B, but lysates were prepared following 1-h PMA
treatment. Lanes 1–3, constitutive TMEFF2 shedding; lanes 4 – 6, PMA-induced processing. Lanes 1 and 4, DAPT-
treated cells show complete loss of the 10-kDa product; lanes 2 and 5, GM6001 inhibition results in reduction in
intensity for the 22- and 14-kDa metalloproteinase fragments and complete loss of the 10-kDa -secretase
product; lanes 3 and 6, vehicle controls showing all three fragments. A GAPDH loading control is shown for PC3
cell lysates.
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3 and 6). Although themetalloproteinase as well as the -secre-
tase inhibitor prevented the formation of the smallest, 10-kDa
fragment, there were only minor differences between treated
and non-treated controls. This suggested to us that shorter
incubation periods were required to assess inhibitor efficacy.
Therefore 1-h PMA stimulation in the presence and absence of
the above inhibitors was used and analyzed byWestern blotting
for the presence of anti-V5 immunoreactive bands in trans-
fected Chinese hamster ovary and PC3 cells (Fig. 2E) or
TMEFF2-expressing HEK293 cells (not shown). GM6001
inhibited the generation of the three C-terminal fragments of
22, 14, and 10 kDa in size (Fig. 2E, lanes 2 and 5) under non-
stimulated and PMA-stimulated conditions when compared
with each appropriate control (Fig. 2E, lanes 3 and 6). Further-
more the -secretase inhibitor DAPT blocked the formation of
the small 10-kDa fragment, whereas it led to the accumulation
of the 14-kDa fragment in the 1-h treatment period (Fig. 2E,
lanes 1 and 4) when compared with the solvent control or
PMA-treated samples, respectively (Fig. 2E, lanes 3 and 6). An
increase in full-length TMEFF2 in cell lysates was not apparent
by Western blot analysis (not shown), which is in good agree-
ment with published data with other proteins such as the amy-
loid precursor protein-like protein (APLP2) (51). This reflects
that only cell surface protein is cleaved from the cellmembrane,
representing a fraction of the total protein. Our data suggest
that both the minor 22- as well as the major 14-kDa fragment
represent products formed by metalloproteinase-dependent
cleavage of TMEFF2, whereas the 10-kDa fragment is the prod-
uct of -secretase-dependent cleavage. Metalloproteinase
cleavage is a prerequisite for -secretase-dependent processing
within the membrane plane (52).
TIMP inhibition studies revealed that neither TIMP1 nor
TIMP2 were able to block the generation of the 14-kDa main
metalloproteinaseC-terminal TMEFF2 fragment as revealed by
Western blot analysis of cell lysates (Table 1). This indicated to
us that neither soluble nor membrane-bound matrix metallo-
proteinases play a role in generating the 14-kDa metallopro-
teinase fragment. In contrast, TIMP3 and TAPI-1, which are
effective inhibitors of ADAMs, prevented the generation of the
14-kDa C-terminal TMEFF2 metalloproteinase fragment indi-
cating that ADAMsmay be responsible for its formation (Table
1). In conclusion, TMEFF2 represents a novel substrate for reg-
ulated intramembrane proteolysis.
Identification of the TMEFF2 “Sheddase(s)”
Having established that PMA-induced TMEFF2 shedding is
dependent on a TIMP3-sensitive metalloproteinase we set out
to identify the proteinase(s) responsible for its processing using
siRNA technology. For this purpose siRNA targeting of
ADAM9, ADAM10, and ADAM17 was used to ablate expres-
sion of these transmembrane metalloproteinases. First we con-
firmed that ADAM10 and ADAM17 expression was signifi-
cantly down-regulated by the respective siRNA toward each
ADAM. As shown in Fig. 3A the signal intensity for ADAM17
protein was dramatically reduced in ADAM17 siRNA-treated
cells (Fig. 3A, lane 1), whereas ADAM17 protein was not
affected by either the scrambled control siRNA or ADAM10
siRNA (Fig. 3A, lanes 2 and 3). ADAM10 protein levels were
also specifically down-regulated by siRNA targeting ADAM10
(Fig. 3A, lane 5), whereas scrambled control siRNA or
FIGURE 3. Identification of the TMEFF2 sheddase using siRNA to down-regulate ADAM9, ADAM10, and ADAM17. A, specificity of ADAM10 and ADAM17
siRNA. Lysates from cells treated with siRNA for 4 days were analyzed by Western blotting (WB) and stained for either the presence of ADAM17 or ADAM10 using
commercial antibodies. Lanes 1–3, stained for ADAM17: lane 1, ADAM17 siRNA; lane 2, ADAM10 siRNA; lane 3, scrambled control siRNA. Lanes 4 – 6, stained for
ADAM10: lane 4, ADAM17 siRNA; lane 5, ADAM10 siRNA; lane 6, scrambled control siRNA. Nonspecific bands are identified with stars, and specific bands are
indicated with arrows. B, TMEFF2 shedding is inhibited by siRNA knockdown of ADAM17 and ADAM10: analysis of lysates from TMEFF2-expressing HEK293 cells
treated with siRNA to ablate ADAM9, ADAM10, and ADAM17 expression for 4 days followed by PMA stimulation for 1 h. Upper panel, TMEFF2 fragments
detected with the V5 epitope antibody: lane 1, untreated control; lane 2, scrambled control siRNA; lane 3, ADAM9 siRNA; lane 4, ADAM10 siRNA; lanes 5 and 6,
ADAM17 siRNA. Note the significant reduction in the signal intensity of the 14-kDa metalloproteinase product in the presence of ADAM17 siRNA. Lower panel,
GAPDH loading control. C, quantification of AP-TMEFF2-ECD release in ADAM siRNA targeted cells: both ADAM10 and ADAM17 contribute to constitutive and
induced TMEFF2 shedding. Single well shedding assays (50) demonstrate that AP-TMEFF2-ECD release depends on ADAM17 under PMA-induced conditions (1-h
incubation). Background AP activity from non-transfected cells was subtracted. Data are represented as mean  S.E. of six replicas, and siRNA treatment is indicated.
TABLE 1
Inhibition of the generation of the 14-kDa metalloproteinase
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ADAM17 siRNA had no effect on the specific bands labeled
with an arrow. Additional nonspecific bands were recognized
by the ADAM10 antibody and are labeled with stars (Fig. 3A,
lanes 4–6). We could not confirm a reduction in ADAM9 pro-
tein expression levels due to a lack of specific commercial
antibodies.
In parallel we analyzed lysates from cells treated for 4 days
with siRNAand stimulated for 1 hwith PMA for the presence of
anti-V5-immunoreactive C-terminal TMEFF2 fragments. As
shown in Fig. 3B down-regulation of ADAM17 expression
reduced the signal intensity of the 14- and 22-kDa metallopro-
teinase fragments (Fig. 3B, lanes 5 and 6). A concomitant com-
plete loss of the 10-kDa -secretase product was also observed.
Densitometric analysis of band intensities was performed and
normalized to the loading control GAPDH (not shown). This
analysis showed that among the ADAMs tested ADAM17 abla-
tion had a significant effect in PMA-induced conditions. In
contrast ADAM9 and ADAM10 siRNA had no effect on the
signal intensity of the 14-kDa fragment.
To further validate our results we used the AP-TMEFF2-
expressing cells tomonitor effects of siRNA treatment to ablate
ADAM expression on AP-TMEFF2-ECD release into condi-
tioned medium using the very sensitive single well shedding
assay (50). Cells were double transfected with siRNA to ablate
the expression of the above ADAMs, and AP-TMEFF2 release
was monitored under constitutive as well as PMA-stimulated
conditions.We demonstrate in Fig. 3C that both ADAM10 and
ADAM17 siRNA treatment significantly inhibited AP-
TMEFF2-ECD release under constitutive conditions. In con-
trast, scrambled and ADAM9 siRNA did not affect cleavage of
AP-TMEFF2 from the cell surface. Following PMA stimulation
only cells treatedwith siRNA toADAM17 showed a diminished
response, suggesting that indeedADAM17 plays amajor role in
TMEFF2 shedding. When calculating the percentage of
increase of AP-TMEFF2-ECD release following siRNA treat-
ment only ADAM17 ablation resulted in a significant reduction
of 65% in the cellular response to PMA stimulation (Table 2). In
contrast, the PMA response in ADAM9, ADAM10, and scram-
bled siRNA-treated cells was not reduced significantly.
An overall loss of released AP activity in ADAM10 as well as
ADAM17 siRNA-treated cells was observed under constitutive
conditions. This may indicate that both enzymes contribute to
constitutive AP-TMEFF2-ECD release from the cell surface.
However, because both ADAM10 and ADAM17 regulate cell
proliferation bymediating availability of-catenin (23) and epi-
dermal growth factor receptor ligands (26), we cannot rule out
that the 4 days of siRNA treatment resulted in unequal cell
numbers when compared with the scrambled control siRNA-
and ADAM9 siRNA-treated cells. Such a scenario would result
in an overall reduction of signal intensity. We have, however,
additional supporting evidence that ADAM10 is involved in
AP-TMEFF2-ECD release as this can be stimulated with the
calcium ionophore ionomycin, a strong inducer of ADAM10
activity (not shown) (53).
The Stalk Sequence Motif of TMEFF2 Is Required for
Constitutive and Induced Shedding
To investigate whether TMEFF2 shedding depended on the
stalk sequence motif we prepared a TMEFF2 mutant lacking
the juxtamembrane stalk sequencemotif (-stalk TMEFF2 and
AP--stalk TMEFF2; Fig. 1) using overlap extension mutagen-
esis (for details see the supplemental information).
First we analyzed cell lysates byWestern blotting for expres-
sion of TMEFF2, -stalk TMEFF2, AP-TMEFF2, and AP--
stalk TMEFF2 to ensure that all proteins were expressed and
not degraded. Fig. 4A shows expression of all four proteins in
cell lysates, suggesting that they are produced in our isogenic
clonal cell lines to a similar level.
We then investigated whether TMEFF2-ECD release was
impaired in HEK293 cells expressing the N-terminally
AP-tagged-stalk TMEFF2mutant and compared ectodomain
release with AP-TMEFF2-expressing cells using the single well
shedding assays (50). As demonstrated in Fig. 4B constitutive as
well as PMA-induced shedding of AP--stalk TMEFF2 was
ablated as these cells showed background AP activity of chlor-
amphenicol transferase-transfected control cells.
Determination of the Biological Activity of TMEFF2
To determine whether TMEFF2 function is dependent on
cell surface localization or whether the soluble ectodomain
was an active growth factor in analogy to the ErbB ligands we
performed additional experiments to answer this important
question.
FIGURE 4. TMEFF2 shedding is dependent on the stalk sequence motif.
A, comparison of wild type and mutant TMEFF2 expression levels in isogenic
clonal HEK293 cells. Western blot analysis of equally loaded cell lysates
stained with the V5 epitope antibody. Lane 1, wild type TMEFF2; lane 2, -stalk
TMEFF2; lane 3, AP-TMEFF2; lane 4, AP--stalk TMEFF2. GAPDH loading con-
trol is indicated. B, comparison of AP-TMEFF2 and AP--stalk TMEFF2 shed-
ding. Single well shedding assays were performed using six replicas for each
treatment and 1-h PMA stimulation (50). Alkaline phosphatase activity was
monitored by hydrolysis of p-nitrophenyl phosphate. Data represented as
mean  S.E. of six replicas.
TABLE 2
PMA response in cells treated with siRNA to ablate specific ADAMs
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TMEFF2-ECD Has Growth-promoting Activity That Depends on
the Complete Ectodomain
We initially used our HEK293 cells expressing soluble
TMEFF2-ECD and vector control cells to investigate whether
the soluble TMEFF2-ECD had growth promoting activity. For
this purpose we used an MTT assay to determine proliferation
rates of these cells and compared these to the rate of vector
control cells. Cells expressing soluble TMEFF2-ECD showed
increased proliferation rates when compared with vector-
transfected controls following statistical analysis using Stu-
dent’s t test (Fig. 5A).
Our initial experiments with soluble TMEFF2-ECD purified
from an overexpressing HEK293 cell line showed that
TMEFF2-ECD had growth factor activity (not shown). We
could not obtain sufficient purified material using mammalian
expression and thus used the maltose-binding fusion proteins
encoding MBP-TMEFF2-ECD and MBP-EGF-TMEFF2 for
further MTT assays. Purified MBP-TMEFF2-ECD and MBP-
EGF-TMEFF2 were expressed in Escherichia coli, and a dose
response (not shown) for effects on proliferation was estab-
lished using non-transfected HEK293 cells. This experiment
revealed that MBP-TMEFF2-ECD was inducing the highest
proliferation rates at an optimal
dose of 10 ng/ml, whereas MBP-
EGF-TMEFF2 was inactive at con-
centrations of up to 100 ng/ml (not
shown). Further proliferation ex-
periments were performed at an
optimal dose of 10 ng/ml MBP-
TMEFF2-ECD using non-trans-
fected HEK293 cells. MTT assays
were performed 4 days later and
revealed that cells treated with solu-
ble MBP-TMEFF2-ECD showed an
over 50% increase in cellular prolif-
eration when compared with mal-
tose-binding protein controls or to
cells treated with MBP-EGF-
TMEFF2, the EGF-like repeat (Fig.
5B). These data suggest that the
EGF-like repeat alone is unable to
promote proliferation under our
experimental conditions and that
the follistatin modules may play an
important role for TMEFF2 func-
tion as a growth factor. Attempts to
express the two follistatin domains
as maltose-binding fusion proteins
failed and thus we cannot narrow
down domain requirements for
function at this point in time.
Inhibition of TMEFF2 Shedding
Reduces Cell Proliferation
We hypothesized that TMEFF2
shedding may contribute to cellular
proliferation due to constitutive
shedding, which occurs in low
serummedium as seen in Fig. 2,B or E (Lysates panel, lane 3) by
the presence of the 14-kDa metalloproteinase product and the
increasedAP activity inAP-TMEFF2-expressing cells (Fig. 2D).
To test this hypothesis we performed proliferation assays in the
presence of the metalloproteinase inhibitor TAPI-1, which
preferentially inhibits ADAMs and previously blocked PMA-
induced shedding by 94% (Table 1). TMEFF2 Me2SO-treated
solvent control cells grew significantly faster than TAPI-1-
treated TMEFF2-expressing cells (Fig. 5C). Me2SO-treated
vector controls showed proliferation rates comparable to those
of TAPI-1-treated TMEFF2 expressing cells or TAPI-1-treated
controls (Fig. 5C). These data reinforce the growth promoting
activity observed previously using TMEFF2-ECD-expressing
cells and stimulation with recombinant TMEFF2-ECD (Fig. 5,
A and B). Vector control cells also responded to TAPI-1 treat-
ment with a reduction in growth rates, but these changes were
not statistically significant using ANOVA and post-test Tukey
analysis.
To see whether the non-cleavable -stalk TMEFF2 mutant
showed significantly different growth rates compared with
those of vector control or TMEFF2-expressing cells we per-
formed additional MTT assays (Fig. 5D). The -stalk TMEFF2
FIGURE 5. Determination of the biological activity of the soluble TMEFF2-ECD and full-length TMEFF2
using overexpressing HEK293 cells. Results of MTT proliferation assays are representative for two independ-
ent experiments performed with six replicas for each treatment unless otherwise stated. Mean  S.E. is shown.
A, overexpression of TMEFF2-ECD increases cell proliferation in HEK293 cells. Statistical analysis was performed
using Student’s t test. B, soluble TMEFF2-ECD but not the EGF domain alone increases HEK293 proliferation.
MTT proliferation assay using 10 ng/ml maltose-binding protein control (MBP-control), MBP-EGF-TMEFF2, or
MBP-TMEFF2-ECD to stimulate HEK293 proliferation. Statistical analysis was performed using ANOVA and
post-test Tukey analysis. C, inhibition of TMEFF2 shedding using TAPI-1 inhibits cell proliferation in HEK293
cells expressing full-length TMEFF2. Statistical analysis was performed using ANOVA and post-test Tukey anal-
ysis. Note that inhibition of TMEFF2 shedding using TAPI-1 showed significant reduction of cell proliferation.
TAPI-1 treatment of vector cells did not cause significant growth inhibition. D, comparison of proliferation rates
of wild type TMEFF2-expressing cells with the -stalk TMEFF2 mutant. Statistical analysis was performed using
ANOVA and post-test Tukey analysis. Note that there is a reduction in proliferation rates expressing -stalk
TMEFF2; however, these are not statistically different to wild type TMEFF2-expressing cells. However, wild type
TMEFF2-expressing cells grew significantly faster than vector controls. E, knockdown of TMEFF2 expression by
siRNA in LNCaP and in TMEFF2-expressing HEK293 cells leads to diminished release of TMEFF2-ECD upon
TNF- stimulation for 12 h. Western blot analysis of concentrated conditioned medium using the anti-TMEFF2
antibody is shown. F, knockdown of TMEFF2 expression by siRNA in LNCaP and in TMEFF2-expressing HEK293
cells decreases proliferation in both cell lines. MTT proliferation assay was performed using 15 replicas per
treatment and analyzed using Student’s t test. n.s., not significant.
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mutant grew at growth rates similar to those of vector controls.
In contrast TMEFF2-expressing cells grew significantly faster
than vector controls using ANOVA post-test Tukey analysis.
The-stalk TMEFF2mutant-expressing cells grew slower than
wild type TMEFF2-expressing cells, which, however, was below
statistical significance. We cannot exclude that some shedding
of the -stalk TMEFF2 mutant may occur over the 4-day time
frame of our proliferation assays thatmay contribute to cellular
growth.
The Role of TMEFF2 in Regulating LNCaP Proliferation
To answer the question whether TMEFF2-ECD functions as
a growth factor in PCa, we then stimulated LNCaP cells with
TMEFF2-ECD and performedMTT assays using the optimized
dose of 10 ng/ml. As shown in supplemental Fig. S1 LNCaP did
not respond to TMEFF2-ECD treatment. Although this was
surprising we argued that potential TMEFF2 receptors on
LNCaPs may be saturated by endogenously released TMEFF2-
ECD, thus allowing no further growth promotion under our
experimental conditions. To answer this hypothesis siRNA
knockdown of TMEFF2 was performed, and effects on prolif-
eration were analyzed.
Knockdown of Endogenous TMEFF2 by siRNA in LNCaP
Cells or TMEFF2-expressing HEK293 Cells Results in
Down-regulation of TNF--induced Shedding
Dharmacon SmartPool siRNA targeting TMEFF2 was trans-
fected using conditions established for the ADAMs followed by
analysis of TNF--induced release of the TMEFF2-ECD into
cell conditioned medium. We used this approach as it was dif-
ficult to monitor TMEFF2 levels in lysates of LNCaPs due to
high background staining of other proteins with the commer-
cial TMEFF2 antibody (not shown). As demonstrated in Fig. 5E
siRNA treatment of LNCaPs or TMEFF2-expressing HEK293
cells followed byTNF--induced shedding resulted in dramatic
reduction of soluble TMEFF2-ECD levels in themediumwhen
compared with scrambled siRNA-treated controls (Fig. 5E,
compare lanes 1 and 2 and lanes 3
and 4). This result demonstrated
that the Dharmacon SmartPool
siRNA reduced TMEFF2 levels
dramatically.
Knockdown of Endogenous
TMEFF2 by siRNA in LNCaP Cells or
TMEFF2-expressing HEK293 Cells
Results in Down-regulation of
Proliferation
To understand the role of
TMEFF2 in prostate cancer, we
used the LNCaP cell line as a model
to address the role of endogenous
TMEFF2 in regulating cell prolifer-
ation. For this purpose siRNA
knockdown of TMEFF2 levels in
these cells was performed and com-
pared with scrambled siRNA con-
trols, and proliferation was meas-
ured using anMTT assay. The targeting of TMEFF2 in LNCaPs
with siRNA resulted in a 15% reduction of proliferation rates
when compared with scrambled controls (Fig. 5F). Further-
more targeting of TMEFF2 in HEK293 cells with siRNA
resulted in a 19% reduction of cell proliferation when com-
pared with scrambled controls (Fig. 5F). Although the levels
in reduction of cell proliferation are relatively small, our
experimental setup is only investigating proliferation effects
due to constitutive release of TMEFF2-ECD, which is very
low (Fig. 2B). Additionally TMEFF2 expression was not com-
pletely abolished by the Dharmacon SmartPool siRNA, thus
still allowing TMEFF2-ECD release in treated cells albeit at a
lower level then scrambled siRNA-treated controls. Never-
theless our results demonstrate that a reduction in TMEFF2
expression levels in LNCaP or our HEK293model system has
antiproliferative effects.
Soluble TMEFF2 Activates ERK1/2 Phosphorylation in an
ErbB1-dependent Manner in HEK293 Cells
To obtain some insight into the signaling mechanism that
might be activated by soluble TMEFF2-ECD to up-regulate
cell proliferation we used non-transfected HEK293 cells as a
model system to test the hypothesis that TMEFF2 might
regulate phosphorylation of ERK1/2 in an ErbB1-dependent
manner. Serum-starved HEK293 cells were stimulated for 5
min with 10 ng/ml TMEFF2-ECD in the presence or absence
of AG1478, a specific ErbB1 tyrosine kinase inhibitor. Cell
lysates were immediately prepared and analyzed by Western
blotting for effects on ERK1/2 phosphorylation. TMEFF2-
ECD stimulated ERK1/2 phosphorylation (Fig. 6A, upper
panel, lane 2), and this response to TMEFF2-ECD was inhib-
ited, by preincubating cells with the synthetic ErbB1 tyrosine
kinase inhibitor AG1478, by 50% (Fig. 6A, upper panel,
lane 4). This result indicated that TMEFF2-ECD was able to
stimulate phosphorylation of ERK1/2 in an ErbB1-depend-
ent fashion.
FIGURE 6. Determination of the TMEFF2-ECD signaling potential and model of TMEFF2 signaling.
A, soluble TMEFF2-ECD induces ERK1/2 phosphorylation in an ErbB1-dependent manner in HEK293 cells.
Serum-starved non-transfected HEK293 cells were stimulated with 10 ng/ml soluble TMEFF2-ECD in the
presence or absence of the ErbB1 tyrosine kinase inhibitor AG1478. Samples were analyzed by Western
blotting using an antibody that recognizes phosphorylated ERK1/2, a downstream target of ErbB1 signal-
ing (upper panel). Lane 1, buffer control; lane 2, soluble TMEFF2-ECD; lane 3, AG1478 alone; lane 4, soluble
TMEFF2-ECD plus AG1478. Blots were stained for GAPDH as a loading control (lower panel). B, schematic
representation of TMEFF2 signaling. TMEFF2-dependent proliferation is inhibited by blocking TMEFF2-
ECD release. The ErbB1 inhibitor AG1478 blocks TMEFF2-ECD-dependent ERK1/2 phosphorylation. EGFR,
EGF receptor.
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DISCUSSION
High TMEFF2 expression levels have been both associated
with growth-promoting and growth-suppressing functions in
various PCa xenograft and cell model systems (1–5). However,
the biological activity of TMEFF2 has remained elusive. We
have here shown that ADAM17-dependent release of the
TMEFF2-ECD regulates TMEFF2 activity and function.
TMEFF2 ectodomain shedding resulted in increased cellular
proliferation that could be suppressed using synthetic metallo-
proteinase inhibitors (Fig. 6B, model of TMEFF2 signaling).
Our results could explain the opposing results from the litera-
ture as proliferation depended onTMEFF2-ECD release, which
had not been studied at the molecular level previously (1–5).
Conceivably membrane-associated TMEFF2 could be growth-
suppressive, although our work does not support this hypothe-
sis (Fig. 5D), which is also in agreement with Afar et al. (1).
Analysis of PMA-induced TMEFF2 shedding revealed that
TMEFF2 is a novel ADAM17 substrate as assessed by siRNA
treatment to ablate expression of this enzyme and quantitative
analysis of AP-TMEFF2-ECD release. Deletion of the jux-
tamembrane stalk sequence in -stalk TMEFF2 showed that
cleavage occurs in this region as shown previously for other
ADAM substrates, such as angiotensin-converting enzyme,
neurotrophin receptor, L-selectin, and the fractalkineCX3CL1,
and other substrates (17, 54–56). Therefore TMEFF2 is a typi-
cal ADAM17 substrate where cleavage depends on the jux-
tamembrane stalk sequence.
The proliferative cellular responses toward ADAM-depend-
ent TMEFF2-ECD release were inhibited by the synthetic met-
alloproteinase inhibitor TAPI-1, suggesting that blocking spe-
cific ADAMs could be of therapeutic benefit in PCa. It is
important to note in this context that different ADAMs have
been assigned critical roles in progression ofmouse PCamodels
by Blobel and co-workers (57, 58) and Kuefer et al. (59). The
W10 mouse prostate cancer model showed well differentiated
tumors in an ADAM9-null background when compared with
ADAM9-positive litter mates, suggesting that ADAM9 con-
tributed significantly to disease progression (57). This was con-
firmed by gain of function studies in which ADAM9 overex-
pression resulted in prostate epithelial hyperplasia and
neoplasia within a year. The authors concluded that this proc-
ess may be due to EGF release by ADAM9 in the prostate epi-
thelial tissue that would activate ErbB1 signaling by an auto-
crine loop. Although siRNA targeting of ADAM9 did not affect
TMEFF2-ECD release under constitutive conditions or follow-
ing PMA induction we currently cannot exclude that ADAM9
may be able to process TMEFF2; this could be tested by gain of
function analysis in ADAM17- or ADAM10-null cells. It would
be useful to use individual or multiple ADAM knock-out cell
lines to establish a complete picture of TMEFF2 sheddases in
the future. However, we have identified that ADAM17 and
ADAM10 (not shown) would contribute to the release of
TMEFF2-ECD.We have also shown that TMEFF2-ECD is able
to induce ErbB1-dependent ERK1/2 phosphorylation albeit in a
different cellular context. Conceivably TMEFF2-ECD could
contribute toward ErbB1-dependent growth-promoting sig-
nals in PCa. In this context it would be interesting to develop
ADAM17 or ADAM10 transgenic prostate cancer models and
investigate their role in this disease in more detail.
It has recently become clear that ADAMs play important
roles in regulating epidermal growth factor receptor/ErbB sig-
naling by releasing active growth factors from the cell surface
(26) with subsequent effects on cell proliferation (14, 46),
migration, and invasion of cancer cells (Refs. 30, 57, 58, and 60;
and for reviews, see Refs. 29 and 61). In PCa ErbB1, ErbB2,
ErbB3, and the ligand EGF are expressed by tumor, whereas six
ErbB ligands are localized in smooth muscle stroma of the
human prostate (62). In mouse PCamodels ADAM12 has been
found to contribute to tumor progression in the carcinoma-
associated stroma by stromal release of growth factors activat-
ing ErbB1 signaling in a paracrine manner (58). We cannot
exclude that ADAM12 may contribute to TMEFF2-ECD
release due to lack of an expression construct to performgain of
function analysis. Recent evidence from both tissue culture
models or animal experiments has indicated that epidermal
growth factor receptor/ErbB1 signaling is associated with and
involved in the development of androgen independence of PCa
and metastasis to bone (63–65). Androgen independence of
PCa was significantly suppressed by ErbB1 tyrosine kinase
inhibitors (63–65). It is important to note in this context that
ErbB1 tyrosine kinase inhibition can be overcomeby the release
of ErbB1 ligands. In breast cancer, inhibition of ADAM17-de-
pendent ligand release has recently been shown to have bene-
ficial effects (66). Thismaywell be true for PCawhereADAM17
and ADAM10 are expressed (60, 67) and would contribute to
TMEFF2-ECD release in our LNCaPmodel. In turn ErbB1 acti-
vation has been shown to increase the half-life of ADAM17 in
breast tumor cells, which may well be the case in other cell
systems and would lead to increased substrate turnover by
tumor cells, aiding the evasion of anti-ErbB therapies (68).
Our structure-function analysis revealed that the TMEFF2-
ECD was able to induce cell proliferation, whereas the EGF
domain alone was inactive when used at the same dose. Among
most EGF-like ligands this is uncommon, but recently the
Xenopus laevis neuregulin1 isoform XeIgNRG12 was shown
to have similar properties. The immunoglobulin-like N-termi-
nal domain of XeIgNRG12 was shown to be involved in the
interaction with ErbB4 allowing signaling and binding at low
doses, whereas the EGF-like domain had to be used at a 1000-
fold higher dose to achieve a biological response (69). Further-
more the proliferation inducing activity of TMEFF2-ECD con-
firms previous work using hippocampal and mesencephalic
neurons, which responded by showing enhanced survival (7),
whereas cortical neurons were non-responsive. Therefore
TMEFF2-ECD function is cell type-specific, whichmay explain
the opposing results published previously in the context of dif-
ferent PCa cell lines or mouse prostate cancer models (1–5).
Our results support a model of TMEFF2 signaling in which
ADAM17 or ADAM10 regulates TMEFF2-ECD release from
TMEFF2-expressing cells (Fig. 6B) allowing autocrine signaling
via ErbB1-dependent ERK1/2 phosphorylation resulting in up-
regulation of cell proliferation. Thismaywell be the case in PCa
whereTMEFF2 is highly expressed. TMEFF2has attracted con-
siderable attention as a prostate cancer-specific cell surface
marker allowing antibody chemotherapy (1, 70). Mice bearing
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xenografted LNCaP and CWR22 prostate cancers expressing
TMEFF2 were treated with monoclonal antibodies conjugated
to auristatin E or with radioactive 90Y, which resulted in signif-
icant and sustained inhibition of tumor growth with no display
of in vivo toxic side effects (1, 70). The soluble TMEFF2 splice
variant (71) as well as TMEFF2-ECD release may, however,
interfere with efficacy of the antibody therapies described
above as these antibodies recognize TMEFF2-ECD. On the
other hand clearance of TMEFF2-ECD antibody complexes
may well be beneficial in suppressing the growth promoting
activity of TMEFF2-ECD.
Our results imply that combinatorial therapeutic approaches
targeting both ErbB1 signaling and ligand release viaADAM17-
dependent shedding should provide an important step toward
preventing tumor growth driven by TMEFF2-ECD released
from the tumor cells. Targeting both ErbB1 signaling and
ADAM17 activity could help to stop PCa progression to andro-
gen-independent metastatic disease that manifests in bone.
Alternatively ADAM17 inhibition in conjunction with existing
TMEFF2 antibody therapies could aid this goal. Such combina-
tion therapy would both block TMEFF2-ECD release from PCa
cells and increase the cell surface expression level of TMEFF2.
This would increase the efficacy of the TMEFF2 antibodies by
directly targeting the tumor cells (1, 70).
Alternatively TMEFF2 may also interact with membrane-
type serine proteinase suppressor of tumorigenicity 14 (ST14)
as recently demonstrated for TMEFF1 (72) and influence cell
surface proteolysis by this interesting enzyme as it is expressed
in human prostate cancer cells (73). However, it is not clear
from Ge et al. (72) whether TMEFF1 is able to inhibit ST14
activity or whether TMEFF1 represents a novel ST14 substrate.
However, their analysis revealed that the interaction between
TMEFF1 and ST14 depended on the EGF-like repeat of
TMEFF1 and the CUB (for complement C1r/C1s, Uegf, Bmp1)
domain of ST14. Clearly further study is needed to fully under-
stand the structure and function of TMEFF2 in prostate cancer.
Acknowledgments—We are grateful to Ruth Stephens, Will English,
Meng Lee, Anthea Messent, and Gillian Murphy for siRNA against
ADAM9, ADAM10, and ADAM17. We thank Mike Sharrad, Anne
Collins, and Norman Maitland for advice on ErbB1 signaling in the
course of this study.
REFERENCES
1. Afar, D. E., Bhaskar, V., Ibsen, E., Breinberg, D., Henshall, S. M., Kench,
J. G., Drobnjak, M., Powers, R., Wong, M., Evangelista, F., O’Hara, C.,
Powers, D., DuBridge, R. B., Caras, I., Winter, R., Anderson, T., Solvason,
N., Stricker, P. D., Cordon-Cardo, C., Scher, H. I., Grygiel, J. J., Sutherland,
R. L., Murray, R., Ramakrishnan, V., and Law, D. A. (2004) Mol. Cancer
Ther. 3, 921–932
2. Mohler, J. L., Morris, T. L., Ford, O. H., III, Alvey, R. F., Sakamoto, C., and
Gregory, C. W. (2002) Prostate 51, 247–255
3. Glynne-Jones, E., Harper, M. E., Seery, L. T., James, R., Anglin, I., Morgan,
H. E., Taylor, K.M., Gee, J.M., andNicholson, R. I. (2001) Int. J. Cancer 94,
178–184
4. Chen, Q.,Watson, J. T., Marengo, S. R., Decker, K. S., Coleman, I., Nelson,
P. S., and Sikes, R. A. (2006) Cancer Lett. 244, 274–288
5. Gery, S., Sawyers, C. L., Agus, D. B., Said, J. W., and Koeffler, H. P. (2002)
Oncogene 21, 4739–4746
6. Uchida, T.,Wada, K., Akamatsu, T., Yonezawa,M., Noguchi, H., Mizogu-
chi, A., Kasuga, M., and Sakamoto, C. (1999) Biochem. Biophys. Res. Com-
mun. 266, 593–602
7. Horie, M., Mitsumoto, Y., Kyushiki, H., Kanemoto, N., Watanabe, A.,
Taniguchi, Y., Nishino, N., Okamoto, T., Kondo, M., Mori, T., Noguchi,
K., Nakamura, Y., Takahashi, E., and Tanigami, A. (2000) Genomics 67,
146–152
8. Liang, G., Robertson, K. D., Talmadge, C., Sumegi, J., and Jones, P. A.
(2000) Cancer Res. 60, 4907–4912
9. Young, J., Biden, K. G., Simms, L. A., Huggard, P., Karamatic, R., Eyre, H. J.,
Sutherland, G. R., Herath, N., Barker, M., Anderson, G. J., Fitzpatrick,
D. R., Ramm, G. A., Jass, J. R., and Leggett, B. A. (2001) Proc. Natl. Acad.
Sci. U. S. A. 98, 265–270
10. Siegel, D. A., Davies, P., Dobrenis, K., and Huang,M. (2006) J. Neurochem.
98, 34–44
11. Grasso, A.W.,Wen,D.,Miller, C.M., Rhim, J. S., Pretlow, T.G., andKung,
H. J. (1997) Oncogene 15, 2705–2716
12. El Sheikh, S. S., Domin, J., Abel, P., Stamp, G., and Lalani, el-N. (2004)
Neoplasia 6, 846–853
13. Lin, H., Wada, K., Yonezawa, M., Shinoki, K., Akamatsu, T., Tsukui, T.,
and Sakamoto, C. (2003) Life Sci. 73, 1617–1627
14. Blobel, C. P. (2005) Nat. Rev. Mol. Cell Biol. 6, 32–43
15. Janes, P. W., Saha, N., Barton, W. A., Kolev, M. V., Wimmer-Kleikamp,
S. H., Nievergall, E., Blobel, C. P., Himanen, J. P., Lackmann, M., and
Nikolov, D. B. (2005) Cell 123, 291–304
16. Horiuchi, K., Zhou, H. M., Kelly, K., Manova, K., and Blobel, C. P. (2005)
Dev. Biol. 283, 459–471
17. Garton, K. J., Gough, P. J., Blobel, C. P.,Murphy, G., Greaves, D. R., Demp-
sey, P. J., and Raines, E. W. (2001) J. Biol. Chem. 276, 37993–38001
18. Anders, L., Mertins, P., Lammich, S., Murgia, M., Hartmann, D., Saftig, P.,
Haass, C., and Ullrich, A. (2006)Mol. Cell. Biol. 26, 3917–3934
19. Reiss, K., Maretzky, T., Ludwig, A., Tousseyn, T., de Strooper, B., Hart-
mann, D., and Saftig, P. (2005) EMBO J. 24, 742–752
20. Nakamura, H., Suenaga, N., Taniwaki, K.,Matsuki, H., Yonezawa, K., Fujii,
M., Okada, Y., and Seiki, M. (2004) Cancer Res. 64, 876–882
21. Hundhausen, C., Misztela, D., Berkhout, T. A., Broadway, N., Saftig, P.,
Reiss, K., Hartmann, D., Fahrenholz, F., Postina, R., Matthews, V., Kallen,
K. J., Rose-John, S., and Ludwig, A. (2003) Blood 102, 1186–1195
22. Hartmann, D., de Strooper, B., Serneels, L., Craessaerts, K., Herreman, A.,
Annaert,W., Umans, L., Lubke, T., Lena, I. A., von Figura, K., and Saftig, P.
(2002) Hum. Mol. Genet. 11, 2615–2624
23. Maretzky, T., Reiss, K., Ludwig, A., Buchholz, J., Scholz, F., Proksch, E., de
Strooper, B., Hartmann, D., and Saftig, P. (2005) Proc. Natl. Acad. Sci.
U. S. A. 102, 9182–9187
24. Reiss, K., Maretzky, T., Haas, I. G., Schulte, M., Ludwig, A., Frank, M., and
Saftig, P. (2006) J. Biol. Chem. 281, 21735–21744
25. Reiss, K., Ludwig, A., and Saftig, P. (2006)Pharmacol. Ther.111, 985–1006
26. Sahin, U., Weskamp, G., Kelly, K., Zhou, H.M., Higashiyama, S., Peschon,
J., Hartmann, D., Saftig, P., and Blobel, C. P. (2004) J. Cell Biol. 164,
769–779
27. Vincent, B., Paitel, E., Saftig, P., Frobert, Y., Hartmann, D., de Strooper, B.,
Grassi, J., Lopez-Perez, E., and Checler, F. (2001) J. Biol. Chem. 276,
37743–37746
28. Fitzgerald, M. L., Wang, Z., Park, P. W., Murphy, G., and Bernfield, M.
(2000) J. Cell Biol. 148, 811–824
29. Fischer, O.M., Hart, S., Gschwind, A., andUllrich, A. (2003)Biochem. Soc.
Trans. 31, 1203–1208
30. Gschwind, A., Hart, S., Fischer, O. M., and Ullrich, A. (2003) EMBO J. 22,
2411–2421
31. Singh, R. J., Mason, J. C., Lidington, E. A., Edwards, D. R., Nuttall, R. K.,
Khokha, R., Knauper, V.,Murphy, G., andGavrilovic, J. (2005)Cardiovasc.
Res. 67, 39–49
32. Amour, A., Knight, C. G., Webster, A., Slocombe, P. M., Stephens, P. E.,
Knauper, V., Docherty, A. J., and Murphy, G. (2000) FEBS Lett. 473,
275–279
33. Amour, A., Slocombe, P.M.,Webster, A., Butler,M., Knight, C. G., Smith,
B. J., Stephens, P. E., Shelley, C., Hutton, M., Knauper, V., Docherty, A. J.,
and Murphy, G. (1998) FEBS Lett. 435, 39–44
34. Murphy, G., Knauper, V., Lee,M.H., Amour, A.,Worley, J. R., Hutton,M.,
ADAM17 Sheds TMEFF2
DECEMBER 28, 2007 • VOLUME 282 • NUMBER 52 JOURNAL OF BIOLOGICAL CHEMISTRY 37387
Atkinson, S., Rapti, M., and Williamson, R. (2003) Biochem. Soc. Symp.
65–80
35. Fedak, P. W., Smookler, D. S., Kassiri, Z., Ohno, N., Leco, K. J., Verma, S.,
Mickle, D.A.,Watson, K. L., Hojilla, C. V., Cruz,W.,Weisel, R. D., Li, R. K.,
and Khokha, R. (2004) Circulation 110, 2401–2409
36. Hojilla, C. V., Kim, I., Kassiri, Z., Fata, J. E., Fang, H., and Khokha, R. (2007)
J. Cell Sci. 120, 1050–1060
37. Mohammed, F. F., Smookler, D. S., Taylor, S. E., Fingleton, B., Kassiri, Z.,
Sanchez, O. H., English, J. L., Matrisian, L. M., Au, B., Yeh, W. C., and
Khokha, R. (2004) Nat. Genet. 36, 969–977
38. Sahebjam, S., Khokha, R., and Mort, J. S. (2007) Arthritis Rheum. 56,
905–909
39. Smookler, D. S., Mohammed, F. F., Kassiri, Z., Duncan, G. S., Mak, T. W.,
and Khokha, R. (2006) J. Immunol. 176, 721–725
40. Hynes, N. E., and Schlange, T. (2006) Cancer Cell 10, 7–11
41. Dempsey, P. J., Garton, K., and Raines, E. W. (2002) Mol. Interv. 2,
136–141
42. Sternlicht, M. D., Sunnarborg, S. W., Kouros-Mehr, H., Yu, Y., Lee, D. C.,
and Werb, Z. (2005) Development 132, 3923–3933
43. Dong, J., Opresko, L. K., Chrisler,W.,Orr, G.,Quesenberry, R. D., Lauffen-
burger, D. A., and Wiley, H. S. (2005)Mol. Biol. Cell 16, 2984–2998
44. Dong, J., Opresko, L. K., Dempsey, P. J., Lauffenburger, D. A., Coffey, R. J.,
and Wiley, H. S. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 6235–6240
45. Yamazaki, S., Iwamoto, R., Saeki, K., Asakura, M., Takashima, S.,
Yamazaki, A., Kimura, R., Mizushima, H., Moribe, H., Higashiyama, S.,
Endoh, M., Kaneda, Y., Takagi, S., Itami, S., Takeda, N., Yamada, G., and
Mekada, E. (2003) J. Cell Biol. 163, 469–475
46. Borrell-Pages, M., Rojo, F., Albanell, J., Baselga, J., and Arribas, J. (2003)
EMBO J. 22, 1114–1124
47. Mosesson, Y., and Yarden, Y. (2004) Semin. Cancer Biol. 14, 262–270
48. Baselga, J. (2001) Eur. J. Cancer 37, Suppl. 1, 18–24
49. Smith, B. L., Chin, D., Maltzman, W., Crosby, K., Hortobagyi, G. N., and
Bacus, S. S. (2004) Br. J. Cancer 91, 1190–1194
50. Sahin, U.,Weskamp,G., Zheng, Y., Chesneau, V., Horiuchi, K., and Blobel,
C. P. (2006)Methods Mol. Biol. 327, 99–113
51. Endres, K., Postina, R., Schroeder, A., Mueller, U., and Fahrenholz, F.
(2005) FEBS J. 272, 5808–5820
52. Xia, W., and Wolfe, M. S. (2003) J. Cell Sci. 116, 2839–2844
53. Horiuchi, K., LeGall, S., Schulte,M., Yamaguchi, T., Reiss, K.,Murphy, G.,
Toyama, Y., Hartmann, D., Saftig, P., and Blobel, C. P. (2007) Mol. Biol.
Cell 18, 176–188
54. Weskamp, G., Schlondorff, J., Lum, L., Becherer, J. D., Kim, T. W., Saftig,
P., Hartmann, D., Murphy, G., and Blobel, C. P. (2004) J. Biol. Chem. 279,
4241–4249
55. Ehlers, M. R., Schwager, S. L., Scholle, R. R., Manji, G. A., Brandt, W. F.,
and Riordan, J. F. (1996) Biochemistry 35, 9549–9559
56. Zhao, L., Shey,M., Farnsworth,M., and Dailey,M. O. (2001) J. Biol. Chem.
276, 30631–30640
57. Peduto, L., Reuter, V. E., Shaffer, D. R., Scher, H. I., and Blobel, C. P. (2005)
Cancer Res. 65, 9312–9319
58. Peduto, L., Reuter, V. E., Sehara-Fujisawa, A., Shaffer, D. R., Scher, H. I.,
and Blobel, C. P. (2006) Oncogene 25, 5462–5466
59. Kuefer, R., Day, K. C., Kleer, C. G., Sabel, M. S., Hofer, M. D., Varambally,
S., Zorn, C. S., Chinnaiyan, A. M., Rubin, M. A., and Day, M. L. (2006)
Neoplasia 8, 319–329
60. Karan, D., Lin, F. C., Bryan, M., Ringel, J., Moniaux, N., Lin, M. F., and
Batra, S. K. (2003) Int. J. Oncol. 23, 1365–1371
61. Arribas, J., Bech-Serra, J. J., and Santiago-Josefat, B. (2006) Cancer Metas-
tasis Rev. 25, 57–68
62. Adam, R. M., Borer, J. G., Williams, J., Eastham, J. A., Loughlin, K. R., and
Freeman, M. R. (1999) Endocrinology 140, 5866–5875
63. Vicentini, C., Festuccia, C., Gravina, G. L., Angelucci, A., Marronaro, A.,
and Bologna, M. (2003) J. Cancer Res. Clin. Oncol. 129, 165–174
64. Angelucci, A., Gravina, G. L., Rucci, N., Millimaggi, D., Festuccia, C.,
Muzi, P., Teti, A., Vicentini, C., and Bologna, M. (2006) Endocr.-Relat.
Cancer 13, 197–210
65. Yazici, S., Kim, S. J., Busby, J. E., He, J., Thaker, P., Yokoi, K., Fan, D., and
Fidler, I. J. (2005) Prostate 65, 203–215
66. Kenny, P. A., and Bissell, M. J. (2007) J. Clin. Investig. 117, 337–345
67. McCulloch, D. R., Harvey, M., and Herington, A. C. (2000) Mol. Cell.
Endocrinol. 167, 11–21
68. Santiago-Josefat, B., Esselens, C., Bech-Serra, J. J., and Arribas, J. (2007)
J. Biol. Chem. 282, 8325–8331
69. Eto, K., Eda, K., Kanemoto, S., and Abe, S. (2006) Biochem. Biophys. Res.
Commun. 350, 263–271
70. Zhao, X. Y., Schneider, D., Biroc, S. L., Parry, R., Alicke, B., Toy, P., Xuan,
J. A., Sakamoto, C., Wada, K., Schulze, M., Muller-Tiemann, B., Parry, G.,
and Dinter, H. (2005) Cancer Res. 65, 2846–2853
71. Quayle, S. N., and Sadar, M. D. (2006) Genomics 87, 633–637
72. Ge, W., Hu, H., Ding, K., Sun, L., and Zheng, S. (2006) J. Biol. Chem. 281,
7406–7412
73. Takeuchi, T., Shuman, M. A., and Craik, C. S. (1999) Proc. Natl. Acad. Sci.
U. S. A. 96, 11054–11061
ADAM17 Sheds TMEFF2
37388 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 282 • NUMBER 52 • DECEMBER 28, 2007
